UBS Maintains Buy on CVS Health, Raises Price Target to $126

Benzinga Newsdesk www.benzinga.com Positive 76.8%

Neg 0% Neu 0% Pos 76.8%

UBS analyst Kevin Caliendo maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $122 to $126.

Comments

No comments yet. Be the first!